Ambrosia Biosciences Unveils Promising Nonclinical Data for a Once-Weekly GLP-1 Receptor Agonist and GIP Receptor Antagonist PipelineAMB-895 and AMB-131 demonstrate highly differentiated PK profiles and robust efficacy in preclinical models